Houttuynia cordata Improves Cognitive Deficits in Cholinergic Dysfunction Alzheimer's Disease-Like Models.
- Author:
Eugene HUH
1
;
Hyo Geun KIM
;
Hanbyeol PARK
;
Min Seo KANG
;
Bongyong LEE
;
Myung Sook OH
Author Information
1. College of Korean Medicine, Kyung Hee University, Seoul 130-701, Republic of Korea.
- Publication Type:Original Article
- Keywords:
Houttuynia cordata;
Cognitive impairment;
Amyloid beta;
Cholinergic dysfunction;
Neuroprotection
- MeSH:
Acetylcholinesterase;
Alzheimer Disease;
Amyloid;
Animals;
Calcium;
Cholinergic Antagonists;
Dementia;
Herbal Medicine;
Hippocampus;
Homeostasis;
Houttuynia*;
Inhibitory Concentration 50;
Memory;
Mice;
Neurons;
Phosphorylation;
Rats;
Tauopathies;
Water
- From:Biomolecules & Therapeutics
2014;22(3):176-183
- CountryRepublic of Korea
- Language:English
-
Abstract:
Cognitive impairment is a result of dementia of diverse causes, such as cholinergic dysfunction and Alzheimer's disease (AD). Houttuynia cordata Thunb. (Saururaceae) has long been used as a traditional herbal medicine. It has biological activities including protective effects against amyloid beta (Abeta) toxicity, via regulation of calcium homeostasis, in rat hippocampal cells. To extend previous reports, we investigated the effects of water extracts of H. cordata herb (HCW) on tauopathies, also involving calcium influx. We then confirmed the effects of HCW in improving memory impairment and neuronal damage in mice with Abeta-induced neurotoxicity. We also investigated the effects of HCW against scopolamine-induced cholinergic dysfunction in mice. In primary neuronal cells, HCW inhibited the phosphorylation of tau by regulating p25/p35 expression in Abeta-induced neurotoxicity. In mice with Abeta-induced neurotoxicity, HCW improved cognitive impairment, as assessed with behavioral tasks, such as novel object recognition, Y-maze, and passive avoidance tasks. HCW also inhibited the degeneration of neurons in the CA3 region of the hippocampus in Abeta-induced neurotoxicity. Moreover, HCW, which had an IC50 value of 79.7 microg/ml for acetylcholinesterase inhibition, ameliorated scopolamine-induced cognitive impairment significantly in Y-maze and passive avoidance tasks. These results indicate that HCW improved cognitive impairment, due to cholinergic dysfunction, with inhibitory effects against tauopathies and cholinergic antagonists, suggesting that HCW may be an interesting candidate to investigate for the treatment of AD.
